GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » Cyclically Adjusted PB Ratio

T2 Biosystems (T2 Biosystems) Cyclically Adjusted PB Ratio : 0.19 (As of May. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems Cyclically Adjusted PB Ratio?

As of today (2024-05-14), T2 Biosystems's current share price is $4.16. T2 Biosystems's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $22.11. T2 Biosystems's Cyclically Adjusted PB Ratio for today is 0.19.

The historical rank and industry rank for T2 Biosystems's Cyclically Adjusted PB Ratio or its related term are showing as below:

TTOO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.11   Med: 2.4   Max: 22.99
Current: 0.2

During the past years, T2 Biosystems's highest Cyclically Adjusted PB Ratio was 22.99. The lowest was 0.11. And the median was 2.40.

TTOO's Cyclically Adjusted PB Ratio is ranked better than
88.64% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.985 vs TTOO: 0.20

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

T2 Biosystems's adjusted book value per share data for the three months ended in Mar. 2024 was $-6.852. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $22.11 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


T2 Biosystems Cyclically Adjusted PB Ratio Historical Data

The historical data trend for T2 Biosystems's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems Cyclically Adjusted PB Ratio Chart

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 12.00 0.25

T2 Biosystems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.72 1.47 4.79 0.25 0.14

Competitive Comparison of T2 Biosystems's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, T2 Biosystems's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


T2 Biosystems's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's Cyclically Adjusted PB Ratio falls into.



T2 Biosystems Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

T2 Biosystems's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.16/22.11
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

T2 Biosystems's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, T2 Biosystems's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-6.852/129.4194*129.4194
=-6.852

Current CPI (Mar. 2024) = 129.4194.

T2 Biosystems Quarterly Data

Book Value per Share CPI Adj_Book
201406 -593.602 100.560 -763.962
201409 306.522 100.428 395.009
201412 264.450 99.070 345.463
201503 215.258 99.621 279.645
201506 167.636 100.684 215.480
201509 117.066 100.392 150.915
201512 194.163 99.792 251.807
201603 144.500 100.470 186.135
201606 92.998 101.688 118.359
201609 166.219 101.861 211.189
201612 129.049 101.863 163.960
201703 85.082 102.862 107.049
201706 40.063 103.349 50.169
201709 50.640 104.136 62.935
201712 3.728 104.011 4.639
201803 -28.004 105.290 -34.422
201806 73.571 106.317 89.558
201809 53.957 106.507 65.565
201812 25.777 105.998 31.473
201903 -3.563 107.251 -4.299
201906 -35.073 108.070 -42.002
201909 -55.511 108.329 -66.318
201912 -67.135 108.420 -80.138
202003 -6.459 108.902 -7.676
202006 -3.416 108.767 -4.065
202009 11.878 109.815 13.998
202012 5.893 109.897 6.940
202103 -0.381 111.754 -0.441
202106 5.435 114.631 6.136
202109 -1.484 115.734 -1.659
202112 -7.754 117.630 -8.531
202203 -14.964 121.301 -15.966
202206 -18.906 125.017 -19.572
202209 -8.983 125.227 -9.284
202212 -513.932 125.222 -531.160
202303 -244.923 127.348 -248.907
202306 -15.060 128.729 -15.141
202309 -4.909 129.860 -4.892
202312 -6.908 129.419 -6.908
202403 -6.852 129.419 -6.852

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


T2 Biosystems  (NAS:TTOO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


T2 Biosystems Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


T2 Biosystems (T2 Biosystems) Business Description

Traded in Other Exchanges
Address
101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.
Executives
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs officer: General Counsel 12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague officer: Chief Financial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii director, officer: See Remarks 61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin officer: Chief Commercial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay officer: SVP, Operations 101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja officer: Chief Medical Officer 101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams director 101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare officer: Chief Commercial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Thierry Bernard director 101 HARTWELL AVENUE, LEXINGTON MA 02421